
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
National report - When it comes to dermatologic treatments that fall outside the mainstream, patients have long found plenty of these on their own. What they don't always find is help in evaluating these treatments' effectiveness.






